Phase 1b Study of NP137 with Atezolizumab-Bevacizumab in First-Line Treatment of Unresectable Hepatocellular Carcinoma

The primary objective of this Phase 1b study is to investigate the association of **NP137** with the **Atezolizumab-Bevacizumab** combination as a first-line treatment in patients with **unresectable hepatocellular carcinoma**. This study aims to evaluate the potential therapeutic benefits and safety profile of this combination therapy in a population where surgical options are not viable. Understanding the efficacy and safety of this treatment regimen is clinically relevant as it may offer a new therapeutic avenue for patients with limited treatment options. No secondary objectives are provided in the available data.

The clinical trial involves participants diagnosed with **unresectable hepatocellular carcinoma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no principal inclusion criteria have been specified. The general health status of the participants is not detailed beyond the specified medical condition.

The clinical trial is designed to evaluate the association of NP137 with the combination of **Atezolizumab** and **Bevacizumab** in patients with **unresectable hepatocellular carcinoma**. This is a Phase 1b study, which is part of a larger Phase 3 trial, and it employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The trial is expected to commence recruitment on March 15, 2023, and is projected to conclude by March 15, 2027, providing a comprehensive evaluation over a four-year period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. Following successful inclusion, participants will be randomized into treatment groups. Regular follow-up visits will be scheduled to monitor the safety and efficacy of the treatment regimen, as well as to collect necessary data for the study endpoints. The end-of-study visit will mark the completion of the participant's involvement, during which final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected duration of participant involvement will vary depending on individual response and the specific protocol requirements, but it is anticipated to span several months. Conditions that may lead to early termination from the study include adverse reactions, withdrawal of consent, or any significant protocol deviations. The study is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the trial duration.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 15, 2023, with an estimated completion date of March 15, 2027. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the available data. The trial will follow a structured timeline to evaluate the efficacy parameters at various stages throughout the study period. The methods for measuring, collecting, and analyzing these parameters will adhere to standard clinical trial protocols, ensuring the reliability and validity of the results. The trial will utilize appropriate tools and instruments to facilitate accurate efficacy assessments, in line with the expectations of a Phase 3 clinical trial. The study will be conducted in accordance with regulatory requirements and ethical standards to ensure the integrity of the data collected.